Get the Stockscreener App
1.33
5.67%
-0.08
After Hours:
1.34
0.01
+0.75%
Nautilus Biotechnology Inc stock is traded at $1.33, with a volume of 198.74K.
It is down -5.67% in the last 24 hours and up +57.42% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
198.74K
Relative Volume:
0.49
Market Cap:
$167.99M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-2.375
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+9.02%
1M Performance:
+57.42%
6M Performance:
+93.15%
1Y Performance:
-48.85%
1-Day Range:
$1.28
$1.4532
1-Week Range:
$1.21
$1.6301
52-Week Range:
$0.62
$2.9181
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.33 | 178.09M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Identifying reversal signals in Nautilus Biotechnology Inc.Weekly Loss Report & Accurate Technical Buy Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is considered a top pickQuarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Strategies to average down on Nautilus Biotechnology Inc.July 2025 Drop Watch & Real-Time Volume Analysis - newser.com
How to recover losses in Nautilus Biotechnology Inc. stock2025 Top Decliners & Community Consensus Trade Signals - newser.com
Long term hold vs stop loss in Nautilus Biotechnology Inc.Market Activity Report & Real-Time Chart Breakout Alerts - newser.com
Has Nautilus Biotechnology Inc. found a price floorJuly 2025 Fed Impact & Stepwise Trade Signal Guides - newser.com
Is Nautilus Biotechnology Inc. stock oversold or undervaluedWeekly Trading Summary & High Accuracy Trade Alerts - newser.com
How geopolitical tensions affect Nautilus Biotechnology Inc. stockJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Can Nautilus Biotechnology Inc. stock weather global recession2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is recommended by analystsJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Earnings visualization tools for Nautilus Biotechnology Inc.July 2025 Outlook & Free Safe Capital Growth Stock Tips - newser.com
Nautilus Biotech Earnings Call Highlights Strategic Progress - TipRanks
Nautilus Biotechnology Inc (NAUT) Q3 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
How Nautilus Biotechnology Inc. stock reacts to oil pricesWeekly Gains Report & Growth Focused Entry Point Reports - newser.com
Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges - TipRanks
How Nautilus Biotechnology Inc. stock performs in rate cut cycles2025 Year in Review & Daily Stock Trend Reports - newser.com
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript - Insider Monkey
Nautilus anticipates early access Tau assay launch in H1 2026 while strengthening proteoform platform partnerships - MSN
Nautilus Biotechnology Advances Toward 2026 Commercial Launch - TipRanks
Nautilus Biotechnology And 2 Other Promising Penny Stocks - Yahoo Finance
Nautilus Biotechnology Narrows Losses And Gains Analyst Confidence - Finimize
Why Nautilus Biotechnology Inc. stock is a must watch in 2025July 2025 Earnings & Accurate Intraday Trading Signals - Fundação Cultural do Pará
Does Nautilus Biotechnology Inc. stock trade at a discount to peersWeekly Stock Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
Earnings call transcript: Nautilus Biotechnology beats Q3 2025 EPS expectations - Investing.com
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results - Investing News Network
Nautilus Biotechnology, Inc. Q3 Loss Decreases, Beats Estimates - Nasdaq
Will Nautilus Biotechnology Inc. stock outperform value stocksWeekly Volume Report & AI Powered Market Entry Ideas - newser.com
Nautilus Biotechnology Incquarterly net loss per share $0.11filing - MarketScreener
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Growth Review: Will Nautilus Biotechnology Inc. stock deliver shareholder valueWeekly Trade Summary & High Win Rate Trade Tips - Fundação Cultural do Pará
Published on: 2025-10-28 04:14:00 - newser.com
Is this a good reentry point in Nautilus Biotechnology Inc.July 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Investing News Network
Published on: 2025-10-28 01:43:09 - newser.com
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):